News | September 02, 2010

SynCardia May Be for Sale in Next 12-24 Months

September 2, 2010 – Artificial heart maker SynCardia Systems said it plans to put the company up for sale some time in the next two years.

The maker of the Total Artificial Heart is considering a series E financing round before it evaluates an exit in the next 12 to 24 months, said CEO Rodger Ford. The company has raised $42.7 million in four rounds of funding to date and may seek an additional $2 to $5 million, said Ford.

SynCardia’s temporary Total Artificial Heart was approved by the FDA in 2004 as a bridge to transplant for transplant-eligible patients dying from end-stage biventricular failure. It is also cleared for use in Europe and Canada.

The company hopes to start a study in 2011 for a destination therapy product, which involves different materials than the current device.

The company plans to ramp up sales of its product and could evaluate an exit in the next 12 to 24 months. Ford said an ideal buyer would be a medical device player, such as Medtronic, Boston Scientific, St. Jude or Abbott. Medtronic and Boston Scientific are considered logical buyers because they may want to acquire cardiac pump devices like SynCardia’s to incorporate with their current offerings of stents and pacemakers.

However, SynCardia may receive greater interest from smaller companies that want to roll up the end-stage heart failure market, said Duane Nash, a senior analyst at Wedbush. He said ventricular assist device (VAD) makers Abiomed or Thoratec may have an interest, since they are already established mechanical circulatory support product vendors. Larger cardiovascular device companies may not consider SynCardia’s market large enough to go after.

Originally used as a permanent replacement heart, the Total Artificial Heart is currently approved as a bridge to human heart transplant for people dying from end-stage biventricular failure. The Total Artificial Heart provides immediate, safe blood flow of up to 9.5 L/min through both ventricles.

For more information:

Related Content

FDA Confirms Impella RP is Safe and Effective
News | Ventricular Assist Devices (VAD) | June 12, 2019
 In a letter sent to healthcare providers, the U.S. Food and Drug Administration (FDA) validates that Abiomed’s Impella...
Impella SmartAssist Platform Launches at SCAI
News | Ventricular Assist Devices (VAD) | May 22, 2019
Abiomed announced that the Impella CP with SmartAssist will be commercially available beginning at the 2019 Society for...
FDA Approves Impella 5.0 and Impella LD Extended Duration of Use
Technology | Ventricular Assist Devices (VAD) | May 14, 2019
The U.S. Food and Drug Administration (FDA) has approved the expansion of Abiomed’s Impella 5.0 and Impella LD...
FDA Approves Initiation of STEMI DTU Pivotal Randomized Controlled Trial
News | Ventricular Assist Devices (VAD) | May 02, 2019
Abiomed announced that, on April 26, the U.S. Food and Drug Administration (FDA) approved initiation of the ST-...
Cardiogenic Shock Survival Rates Improve in Three Years Since Impella FDA Approval
News | Ventricular Assist Devices (VAD) | April 05, 2019
Three years ago this week, Abiomed's Impella heart pump received U.S. Food and Drug Administration (FDA) premarket...
HeartMate 3 Pump Shows Superior Outcomes in Advanced Heart Failure
News | Ventricular Assist Devices (VAD) | March 22, 2019
Severely ill patients with advanced heart failure who received the HeartMate 3 left ventricular assist device (LVAD)...
Leviticus Cardio and Jarvik Heart Unveil Wireless Heart Pump System
News | Ventricular Assist Devices (VAD) | February 11, 2019
Heart failure experts at the National Research Center for Cardiac Surgery in Astana, Kazakhstan, recently announced the...
Medtronic Receives FDA Approval for Less-Invasive Heart Pump Implant Procedure
Technology | Ventricular Assist Devices (VAD) | July 17, 2018
Medtronic plc recently received U.S. Food and Drug Administration (FDA) approval for a less-invasive implant approach...
CorWave's Next-generation Neptune LVAD Receives Funding

Image courtesy of CorWave

News | Ventricular Assist Devices (VAD) | July 11, 2018
French-based CorWave announced that its CALYPSO program has received 14 million euros to develop CorWave Neptune, a new...
Overlay Init